PARDES BIOSCIENCES, INC.
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY22 | FY21 | FY20 | |
|---|---|---|---|
| Revenue | $0 | $0 | — |
| Operating income | — | $38.5M | $5.3M |
| Net income | −$96.6M | −$38.5M | −$13.0M |
| Total assets | $200.6M | $275.3M | $3.6M |
| Total liabilities | $20.4M | $9.0M | $16.6M |
| Equity | $180.2M | $266.3M | −$13.0M |
| EPS (diluted) | $-1.66 | $-10.13 | — |
| Shares out. | 62.4M | 56.8M | 0 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2022- Operating margin
- —
- Net margin
- —
- Return on equity
- −53.6%
- Return on assets
- −48.2%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 10.2%
- Debt / equity
- 0.11×
- Book value / share
- $2.89
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2022- Accruals / assets
- −12.3%clean
- Piotroski F-Score
- 1/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 warning● 2 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Tananbaum James B.Officer — President and CEO | Aug 31, 2023 | D | 16.8M | — |
| Wiggans Thomas GOfficer — Chief Executive Officer | Aug 31, 2023 | U | 50,000 | — |
| Varney Michael DavidDirector | Aug 31, 2023 | U | 70,390 | — |
| Lopatin Uri ADirector | Aug 31, 2023 | U | 5.3M | — |
| Lobell J JayDirector | Aug 31, 2023 | U | 200,000 | — |
| Lacy Elizabeth H.Officer — General Counsel, Secretary | Aug 31, 2023 | U | 211,169 | — |
| Henson HeidiOfficer — Chief Financial Officer | Aug 31, 2023 | U | 316,753 | — |
| Auerbach MarkDirector | Aug 31, 2023 | U | 70,390 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventAug 31, 2023
- Entered a material agreement · Director / officer change · Regulation FD disclosureJul 17, 2023
- Director / officer change · Shareholder voteJun 5, 2023
- Director / officer changeMay 18, 2023
- Results of operationsMay 5, 2023
- Director / officer changeApr 21, 2023
- Results of operations · Costs from exit or disposal · Regulation FD disclosure · Other material eventApr 3, 2023
- Results of operationsMar 14, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- CT ORDERSep 18, 2023
- 15-12GSep 11, 2023
- EFFECTAug 31, 2023
- EFFECTAug 31, 2023
- 4Aug 31, 2023
- SC 13D/AAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023
- 4FORM 4 SUBMISSIONAug 31, 2023